KRBP
Income statement / Annual
Last year (2024), Kiromic BioPharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Kiromic BioPharma, Inc.'s net income was -$26.90 M.
See Kiromic BioPharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$2.80 M
|
$2.07 M
|
$469.80 K
|
$200.00 K
|
$87.50 K
|
$80.90 K
|
| Gross Profit |
$0.00
|
-$2.80 M
|
-$2.07 M
|
-$469.80 K
|
-$200.00 K
|
-$87.50 K
|
-$80.90 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$6.85 M
|
$9.62 M
|
$13.92 M
|
$11.37 M
|
$5.05 M
|
$1.20 M
|
$1.42 M
|
| General & Administrative Expenses |
$8.85 M
|
$10.31 M
|
$17.19 M
|
$13.94 M
|
$14.14 M
|
$2.50 M
|
$1.76 M
|
| Selling & Marketing Expenses |
$0.00
|
-$2.80 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.85 M
|
$7.52 M
|
$17.19 M
|
$13.94 M
|
$14.14 M
|
$2.50 M
|
$1.76 M
|
| Other Expenses |
$8.07 M
|
$0.00
|
$0.00
|
$53.40 K
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$23.77 M
|
$17.14 M
|
$31.11 M
|
$25.31 M
|
$19.20 M
|
$3.71 M
|
$3.18 M
|
| Cost And Expenses |
$0.00
|
$19.94 M
|
$31.11 M
|
$25.31 M
|
$19.20 M
|
$3.71 M
|
$3.18 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
-$3.72 M
|
-$1.85 M
|
$166.50 K
|
$12.20 K
|
$3.30 K
|
$22.50 K
|
$633.10 K
|
| Depreciation & Amortization |
$6.85 M
|
$2.80 M
|
$2.07 M
|
$469.80 K
|
$200.00 K
|
$87.50 K
|
$80.90 K
|
| EBITDA |
-$23.77 M |
-$16.30 M |
-$32.50 M |
-$25.11 M |
-$19.00 M |
-$3.62 M |
-$3.10 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$3.12 M
|
-$1.01 M
|
-$3.62 M
|
$147.00 K
|
-$3.30 K
|
-$22.50 K
|
-$633.10 K
|
| Income Before Tax |
-$26.90 M
|
-$20.95 M
|
-$34.73 M
|
-$25.59 M
|
-$19.20 M
|
-$3.73 M
|
-$3.82 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$26.90 M
|
-$21.29 M
|
-$38.18 M
|
-$25.65 M
|
-$19.20 M
|
-$3.75 M
|
-$3.82 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.03 |
-21.41 |
-70.12 |
-67.4 |
-79.08 |
-29 |
-32.4 |
| EPS Diluted |
-1.03 |
-21.41 |
-70.12 |
-67.4 |
-79.08 |
-29 |
-32.4 |
| Weighted Average Shares Out |
$26.07 M
|
$32.93 M
|
$16.34 M
|
$11.42 M
|
$7.28 M
|
$3.88 M
|
$3.53 M
|
| Weighted Average Shares Out Diluted |
$26.07 M
|
$32.93 M
|
$16.34 M
|
$11.42 M
|
$7.28 M
|
$3.88 M
|
$3.53 M
|
| Link |
|
|
|
|
|
|
|
